Mach7 Technologies Ltd (ASX: M7T) Share Price and News

Price

Movement

( )

(20 mins delayed)

52 Week Range

-

 
1 Year Return

 

Mach7 Technologies Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $83.23 million
P/E Ratio 1,428.57
Dividend Yield 0.00%
Shares Outstanding 241.24 million
Earnings per share -0.022
Dividend per share N/A
Year To Date Return -13.75%
Earnings Yield 0.07%
Franking -
Share Price

Day Change

( )

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

Mach7 Technologies Ltd (ASX: M7T)
Latest News

A businessman leaps in the air outside a city building in the CBD.
Healthcare Shares

Mach7 signs $17 million contract – share price jumps 20% at open

Shares in the ASX listed medical imaging systems provider leapt more than 20% on open.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face due to his ASX shares going up and in particular the Computershare share price
Share Gainers

Why AGL, Invictus Energy, Maas, and Mach7 shares are pushing higher today

These ASX shares are having positive days...

Read more »

A woman is excited as she reads the latest rumour on her phone.
Small Cap Shares

Broker names 2 small cap ASX shares to buy now

Morgans is bullish on these small cap shares...

Read more »

Kid on a skateboard with cardboard wings soars along the road.
Small Cap Shares

Broker names 2 small cap ASX shares to buy in September

These small cap ASX shares could be buys...

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Share Market News

Brokers rate these 2 top ASX shares as buys in June 2022

These two ASX shares could be top ideas, according to brokers.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Small Cap Shares

3 promising small cap ASX shares to watch

Keep an eye on these small cap shares...

Read more »

two doctors smile as they sit together at a desk looking at a patient's Xray.
Healthcare Shares

Why the Mach7 (ASX:M7T) share price is roaring 6% higher today

Mach7's revenues are set for a much welcomed boost.

Read more »

a small person in business attire stands next to a very tall person with only their legs in the image.
Small Cap Shares

2 small-cap ASX shares with an edge over rivals

An expert picks a pair of smaller businesses that are doing all the right things to grow into a larger…

Read more »

share price gaining
Small Cap Shares

2 growing small cap ASX shares to watch

These ASX small cap shares could be ones to watch...

Read more »

a concerned medical doctor examines an Xray from an imaging machine in a hospital setting.
Share Market News

Mach7 (ASX:M7T) share price slides on mixed FY21 result

The company's share price ended the day on a down note.

Read more »

asx share price on watch represented by group of prople all looking through magnifying glasses
Small Cap Shares

3 small cap ASX shares to watch

Keep an eye on these small cap shares...

Read more »

sad, unhappy medical worker, medical share price fall, drop, decrease,
Share Market News

Mach7 (ASX:M7T) share price stumbles 8% on business update

It's not a good day for the ASX-listed medical imaging company.

Read more »

Frequently Asked Questions

M7T ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Mach7 Technologies Ltd

Mach7 Technologies Ltd (ASX: M7T) is a medical imaging systems provider that develops innovative image management and viewing solutions for healthcare organisations. Its systems create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. This allows healthcare enterprises to identify, connect, and share diagnostic image and patient care intelligence.

Mach7 has more than 150 customers in 15 countries and derives a majority of its revenue from North America.

M7T Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
02 May 2025 $0.35 $0.00 0.00% 110,298 $0.35 $0.35 $0.35
01 May 2025 $0.35 $0.01 2.99% 284,083 $0.34 $0.36 $0.34
30 Apr 2025 $0.34 $0.02 6.25% 904,877 $0.33 $0.38 $0.33
29 Apr 2025 $0.32 $-0.01 -3.03% 222,584 $0.33 $0.34 $0.32
28 Apr 2025 $0.33 $0.01 3.08% 151,578 $0.33 $0.33 $0.33
24 Apr 2025 $0.33 $0.00 0.00% 107,559 $0.33 $0.33 $0.33
23 Apr 2025 $0.33 $-0.01 -3.03% 506,918 $0.33 $0.33 $0.33
22 Apr 2025 $0.33 $0.00 0.00% 97,038 $0.33 $0.33 $0.33
17 Apr 2025 $0.33 $0.00 0.00% 86,323 $0.33 $0.33 $0.32
16 Apr 2025 $0.33 $0.01 3.13% 122,105 $0.32 $0.33 $0.32
15 Apr 2025 $0.32 $0.02 6.56% 83,117 $0.31 $0.32 $0.31
14 Apr 2025 $0.31 $0.00 0.00% 176,764 $0.29 $0.32 $0.29
11 Apr 2025 $0.31 $-0.01 -3.17% 68,033 $0.31 $0.31 $0.31
10 Apr 2025 $0.32 $0.02 6.78% 485,871 $0.30 $0.32 $0.30
09 Apr 2025 $0.30 $-0.02 -6.45% 156,310 $0.32 $0.32 $0.29
08 Apr 2025 $0.31 $0.00 0.00% 126,370 $0.31 $0.31 $0.31
07 Apr 2025 $0.31 $-0.01 -3.13% 437,974 $0.31 $0.31 $0.28
04 Apr 2025 $0.32 $-0.01 -3.03% 458,989 $0.33 $0.33 $0.32

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
31 Dec 2024 Eliot Siegel Buy 112,012 $44,143
On-market trade.
12 Dec 2024 Mike Lampron Buy 46,000 $16,330
On-market trade.
09 Dec 2024 Mike Lampron Issued 800,000 $284,000
Issue of securities. 2,223,000 Performance Rights
05 Dec 2024 Robert Bazzani Buy 54,700 $19,998
On-market trade.
03 Dec 2024 Robert Bazzani Buy 27,395 $9,999
On-market trade.
02 Dec 2024 Robert Bazzani Buy 53,333 $19,962
On-market trade.
28 Nov 2024 Rebecca Thompson Buy 400,000 $148,000
On-market trade.
19 Nov 2024 Robert Bazzani Expiry 225,000 $81,000
Options expired.
19 Nov 2024 Eliot Siegel Expiry 25,000 $9,000
Options expired.
19 Nov 2024 Mike Lampron Expiry 750,000 $270,000
Options expired.
30 Sep 2024 Mike Lampron Expiry 402,185 $223,212
As advised by the company. 1,423,000 Performance Rights, lapsed
21 May 2024 Robert Bazzani Buy 29,400 $19,944
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Eliot L Siegel Non-Executive Director Aug 2018
Dr. Siegel is a thought leader in the world of radiology and imaging informatics and artificial intelligence applications in medicine. He is currently Professor at the University of Maryland School of Medicine, Department of Diagnostic Radiology, and also works for the Veterans Affairs Maryland Healthcare System, in Baltimore, MD as well as adjunct professor of computer science and biomedical engineering at the undergraduate campuses of the University of Maryland. He is a pioneer and co-founder of United Theranostics, a company created to bring state-of-the-art radiopharmaceuticals to patients for cancer therapy. Under his guidance, the VA Maryland Healthcare System became the first filmless healthcare enterprise in the World. He has written over 300 articles and book chapters about PACS (Picture Archiving and Communication Systems) and digital imaging, and has edited books on the topic, including Filmless Radiology and Security Issues in the Digital Medical Enterprise. He has given more than 1,000 presentations throughout the world on a range of topics involving the use of computers in medicine and artificial intelligence. Dr. Siegel was symposium chairman for the Society of Photo-optical and Industrial Engineers (SPIE) Medical Imaging Meeting for three years and has been honored as a fellow in that organisation as well as the American College of Radiology and the Society of Imaging Informatics in Medicine. He is also a Board member of Carestream Health and serves on advisory boards in medical imaging. He us Risk Management Committee member. Former directorships (last 3 years): Carestream Health.
Mr Mike Lampron Chief Operating OfficerChief Executive OfficerManaging Director Mar 2019
Mr. Lampron is the CEO of Mach7 Technologies. With over 20 years of experience in business and operational management for Healthcare IT companies, Michael brings experience ranging from private start-up organizations as well as established companies such as IBM and GE. Michael was previously the Chief Executive Officer for a National Teleradiology Company and has ability to drive results through a combination of astute analysis, innovative execution and cross-functional teamwork. Michael is responsible for our customers' success while driving excellence throughout Mach7. Former directorships (last 3 years): Watchtower Consultants, LLC.
Mr Robert John Bazzani Non-Executive ChairmanNon-Executive Director Jan 2020
Mr Bazzani spent 20 years with the global consulting firm KPMG, where he rose to the top and served as Chairman of KPMG Victoria, National Managing Partner for KPMG Australia's Enterprise Division and National Managing Partner for KPMG's M&A Division. Whilst in these roles, Rob was a member of KPMG's National Executive Committee (NEC), which oversees and is responsible for the Firm's turnover, strategic decision making, profitability and operations. Rob has a track record of leading and growing businesses. He has played a role in advising clients (public, private, and global subsidiaries) on commercial matters, public transitions, corporate governance, investment banking and law, M&A and has engaged with Government and Regulators. With experience in corporate advisory, Rob has deep commercial and industry knowledge across financial services, asset and wealth management, technology, property, insurances and consumer & industrial markets. He is Risk Management Committee member.
Ms Rebecca Thompson Non-Executive Director Nov 2023
Ms Thompson has more than 25 years of financial markets experience gained at global investment banks, listed companies and a fintech start-up. Rebecca's executive career included seven years at J.P, Morgan as the Head of Corporate Broking followed by a role at KPMG Australia as the Head of Capital Advisory and most recently Head of Investor Relations for CSR Limited (ASX:CSR). Rebecca has a skillset across equities, property, and foreign exchange with experience in the real estate, building materials, healthcare, resources and software industries. Stakeholder relations, communications, sustainability and financial analysis are core competencies Other current directorships: Independent Community Living Australia (ICLA), Non-Executive Director; MarketMeter, Non-Executive Director. He is risk Management Committee Chair.
Mr Tony Panther Company Secretary Feb 2023
-
Tony Panther Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
National Nominees Limited 32,877,317 13.63%
Sandhurst Trustees Ltd (Jmfg Consol A/C) 31,114,880 12.90%
J P Morgan Nominees Australia Pty Limited 27,668,371 11.47%
HSBC Custody Nominees (Australia) Limited 22,684,257 9.40%
Citicorp Nominees Pty Limited 9,721,484 4.03%
Ubs Nominees Pty Ltd 9,233,020 3.83%
Pt Dwi Satrya Utama 4,392,959 1.82%
Padmalwar Prakash 3,569,921 1.48%
Chew & Partners (Import & Export) Pte Ltd 2,900,074 1.20%
Perco Group Pty Ltd (F S P A/C) 2,840,000 1.18%
Microequities Asset Management Pty Ltd (Microeqts Nanocap No 11 A/C) 2,823,641 1.17%
BNP Paribas Nominees Pty Ltd (Ib Au Noms Retailclient) 1,718,707 0.71%
Supernatural Super Pty Ltd (The Supernatural Super A/C) 1,715,500 0.71%
Albert Liong Pak-Fai 1,544,189 0.64%
Bpnt Pty Ltd (Heaney Family Super Fund A/C) 1,539,283 0.64%
Ty Webb Pty Ltd (Ty Webb A/C) 1,339,444 0.56%
BNP Paribas Noms Pty Ltd 1,303,411 0.54%
Mrs Jennifer Lee Pilcher 1,294,856 0.54%
62 Darlinghurst Road Pty Ltd 1,000,000 0.41%
HSBC Custody Nominees (Australia) Limited (Gsco Customers A/C) 964,287 0.40%

Profile

since

Note